Last $46.24 USD
Change Today +0.90 / 1.99%
Volume 213.4K
PODD On Other Exchanges
Symbol
Exchange
Berlin
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (PODD) Snapshot

Open
$45.64
Previous Close
$45.34
Day High
$46.47
Day Low
$44.50
52 Week High
03/21/14 - $51.31
52 Week Low
08/8/14 - $30.04
Market Cap
2.6B
Average Volume 10 Days
450.7K
EPS TTM
$-0.60
Shares Outstanding
56.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSULET CORP (PODD)

insulet corp (PODD) Related Bloomberg News

View More Bloomberg News

insulet corp (PODD) Related Businessweek News

No Related Businessweek News Found

insulet corp (PODD) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and a handheld, wireless personal diabetes manager. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors. Insulet Corporation was founded in 2000 and is based in Bedford, Massachusetts.

478 Employees
Last Reported Date: 02/28/14
Founded in 2000

insulet corp (PODD) Top Compensated Officers

Director of Advanced Technology and Director
Total Annual Compensation: $376.9K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Executive Officer
Total Annual Compensation: $330.4K
Consultant
Total Annual Compensation: $448.4K
Compensation as of Fiscal Year 2013.

insulet corp (PODD) Key Developments

Insulet Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:00 PM

Insulet Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

Insulet Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 09:45 AM

Insulet Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 09:45 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Brian K. Roberts, Executive Officer, Patrick J. Sullivan, Chief Executive Officer, President and Director.

Insulet Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Revenue Guidance for the Full Year Ending December 31, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014

Insulet Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, revenue was $74.985 million against $61.103 million a year ago. Operating loss was $2.876 million against $17.313 million a year ago. Loss before income taxes was $10.824 million against $21.285 million a year ago. Net loss was $10.845 million or $0.19 per basic and diluted share against $21.285 million or $0.39 per basic and diluted share a year ago. For the nine months, revenue was $216.159 million against $178.551 million a year ago. Operating loss was $10.042 million against $29.341 million a year ago. Loss before income taxes was $45.962 million against $42.220 million a year ago. Net loss was $43.100 million or $0.83 per basic and diluted share against $42.474 million or $0.79 per basic and diluted share a year ago. For the year ending December 31, 2014, the company revised its estimate of revenue to be in the range of $292 to $297 million. For the fourth quarter of 2014, the company expects that revenue will be in the range of $76 to $81 million. The company expects further improvements in consolidated gross margins through a combination of additional component price reductions and incremental overhead leverage with the start of a fourth manufacturing line. The company expects to record interest expense related to the 2% notes of approximately $3 million per quarter, comprised of $1 million in cash interest expense and $2 million in noncash interest expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $46.24 USD +0.90

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $139.90 USD +1.44
DexCom Inc $54.94 USD +0.99
Smiths Group PLC 1,100 GBp -8.00
Takeda Pharmaceutical Co Ltd ¥5,057 JPY -7.00
Tandem Diabetes Care Inc $12.98 USD -0.02
View Industry Companies
 

Industry Analysis

PODD

Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 32.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.